FibroBiologics wins new US patent for degenerative disc disease treatment using fibroblast conditioned media
FBLG•Regenerative growth factors and delivery methods
The approach targets higher regenerative growth factor output, including EGF, to stimulate proteoglycan synthesis.
Delivery is envisioned via direct injection into the disc or systemic administration.
Patent covers fibroblast conditioned media for disc disease
FibroBiologics received U.S. Patent No. 12,716,055 covering fibroblast conditioned media to treat degenerative disc disease.
The claims include disc regeneration methods using fibroblasts cultured with opioid receptor antagonists plus TLR agonists.
